Compare NLOP & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | SGHT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.9M | 395.5M |
| IPO Year | N/A | 2021 |
| Metric | NLOP | SGHT |
|---|---|---|
| Price | $20.50 | $7.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $46.00 | $7.66 |
| AVG Volume (30 Days) | 207.5K | ★ 298.2K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 59.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $115,901,000.00 | $76,052,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.60 | $2.03 |
| 52 Week High | $34.53 | $9.24 |
| Indicator | NLOP | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 15.99 | 47.22 |
| Support Level | $25.45 | $7.28 |
| Resistance Level | $26.19 | $9.24 |
| Average True Range (ATR) | 0.65 | 0.61 |
| MACD | -0.41 | -0.19 |
| Stochastic Oscillator | 7.71 | 24.03 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.